Latest News
GSK secures China approval for Blenrep in relapsed multiple myeloma
20 April 2026 - Biopharmaceutical company GSK plc (LSE: GSK) (NYSE: GSK) declared on Monday that it has received approval from China's National Medical Products Administration for Blenrep (belantamab mafodotin) in combination with bortezomib and...
Sanofi's Nuvaxovid demonstrates superior tolerability to Moderna's mNEXSPIKE in phase 4 study
20 April 2026 - French healthcare company Sanofi S.A. (Euronext Paris:SAN) (Nasdaq:SNY) announced on Saturday that its protein-based COVID-19 vaccine, Nuvaxovid (NVX-CoV2705), showed statistically significant lower systemic reactogenicity compared to...
AstraZeneca reports third positive Phase III trial for tozorakimab in COPD
20 April 2026 - Biopharmaceutical company AstraZeneca PLC (LSE: AZN) (STO: AZN) (NYSE: AZN) on Monday reported positive high-level results from the Phase III MIRANDA trial, demonstrating that its IL-33-targeting biologic, tozorakimab, achieved a stat...
TheraCryf advances Ox-1 programme to clinical stage following successful GMP manufacture
20 April 2026 - TheraCryf plc (AIM: TCF), a biotechnology company developing new medicines for addiction and other neuropsychiatric disorders, revealed on Monday that it has completed the Good Manufacturing Practice (GMP) production of over 2kg of cl...
Accent Therapeutics presents ATX-295 data at AACR Annual Meeting 2026
20 April 2026 - Clinical-stage biopharmaceutical company Accent Therapeutics on Friday presented preclinical data supporting its potentially best-in-class KIF18A inhibitor, ATX-295, at the American Association for Cancer Research (AACR) Annual Meetin...